Genes controlling spread of breast cancer to lung gang of 4

Experimental Oncology

Volumn 30, Issue 2, 2008, Pages 91-95

  Eltarhouny, S A ^a,b   Elsawy, W H ^b   Radpour, R ^a   Hahn, S ^a   Holzgreve, W ^a   Zhong, X Y ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

Breast cancer; COX2; EPREG; Metastasis; MMPs

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; BLOOD CLOTTING FACTOR 12; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; EPIREGULIN; FAS LIGAND; FIBRINOGEN; FIBROBLAST GROWTH FACTOR 1; GELATINASE A; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; ILOMASTAT; INTERLEUKIN 1; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 14; MONOCYTE CHEMOTACTIC PROTEIN 3; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN; STROMAL CELL DERIVED FACTOR 1; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

BREAST CANCER; CANCER CONTROL; CANCER MORTALITY; COX2 GENE; EREG GENE; GENE; GENE IDENTIFICATION; HUMAN; LUNG METASTASIS; MMP 1 GENE; MMP 2 GENE; NONHUMAN; REVIEW; TUMOR GROWTH;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DISEASE PROGRESSION; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MODELS, BIOLOGICAL; MODELS, GENETIC; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS;

EID: 46749102558     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Gupta GP, Nguyen DX, Chiang AC , et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007; 446: 765-70.
2. Toyoda H, Komurasaki T, Lchida D, et al. Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem 1995; 270: 7495-500.
3. Komurasaki T, Toyoda H, Uchida D, Morimoto S. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. Oncogene 1997; 15:2841-8.
4. Shelly M, Pinkas-Kramarski R, Guarino BC, et al. Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem 1998; 273: 10496-505.
5. Toyoda H, Komurasaki T, Ikeda Y, et al. Molecular cloning of mouse epiregulin, a novel epidermal growth factor-related protein, expressed in the early stage of development. FEBS Lett 1995; 377: 403-7.
6. Sasaki E, Arakawa T, Fujiwara Y, et al. Epiregulin stimulates proliferation of rabbit gastric cells in primary culture through autophosphorylation of the epidermal growth factor receptor. Eur J Pharmacol 1997; 338: 253-8.
7. Shirakata Y, Komurasaki T, Toyoda H, et al. Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes. J Biol Chem 2000; 275: 5748-53.
8. Taylor DS, Cheng X, Pawlowski JE, et al. Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. PNAS USA 1999; 96: 1633-8.
9. Baba I, Shirasawa S, Iwamoto R, et al. Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. Cancer Res 2000; 60: 6886-9.
10. Ejskjaer K, Sorensen BS, Poulsen SS, et al. Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecol Oncol 2007; 104: 158-67.
11. Torring N, Jorgensen PE, Sorensen BS, Nexo E. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 2000; 20: 91-5.
12. Zhu Z, Kleeff J, Friess H, et al. Epiregulin is up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun 2000; 273: 1019-24.
13. Minn AJ, Gupta GP, Padua D, et al. Lung metastasis genes couple breast tumor size and metastatic spread. PNAS USA 2007; 104: 6740-5.
14. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-24.
15. Lievre A, Laurent-Puig P. Predictive factors of response to anti-EGFR treatments in colorectal cancer. Bull Cancer 2008; 95: 133-40.
16. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008; 40: 1362-78.
17. Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 2007; 42: 113-85.
18. Harikumar KB, Aggarwal BB. Resveratrol: A multi-targeted agent for age-associated chronic diseases. Cell Cycle 2008; 7 [Epub].
19. Amalinei C, Caruntu ID, Balan RA. Biology of metalloproteinases. Rom J Morphol Embryol 2007; 48: 323-34.
20. Hamacher S, Matern S, Roeb E. Extracellular matrix -from basic research to clinical significance. An overview with special consideration of matrix metalloproteinases. Dtsch Med Wochenschr 2004; 129: 1976-80 (In German).
21. Minond D, Lauer-Fields JL, Nagase H, Fields GB. Matrix metalloproteinase triple-helical peptidase activities are differentially regulated by substrate stability. Biochemistry 2004; 43: 11474-81.
22. Duffy MJ, McGowan PM, Gallagher WM. Cancerinvasion and metastasis: changing views. J Pathol 2008; 214: 283-93.
23. Sunami E, Tsuno N, Osada T, et al. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist 2000; 5: 108-14.
24. D'Andrea MR, Limiti MR, Bari M, et al. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res Treat 2007; 101: 279-84.
25. Lei H, Hemminki K, Altieri A, et al. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat 2007; 103: 61-9.
26. Takino T, Saeki H, Miyamori H, et al. Inhibition of membrane-type 1 matrix metalloproteinase at cell-matrix adhesions. Cancer Res 2007; 67: 11621-9.
27. Kawano N, Osawa H, Ito T, et al. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol 1997; 28: 613-22.
28. Luo J. Role of matrix metalloproteinase-2 in ethanol-induced invasion by breast cancer cells. J Gastroenterol Hepatol 2006; 21: S65-8.
29. Trudel D, Fradet Y, Meyer F, et al. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum Pathol 2008; 39: 731-9.
30. Guo CB, Wang S, Deng C, et al. Relationship between matrix metalloproteinase 2 and lung cancer progression. Mol Diagn Ther 2007; 11: 183-92.
31. Mendes O, Kim HT, Lungu G, Stoica G. MMP-2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin Exp Metastasis 2007; 24: 341-51.
32. Duffy MJ. Do proteases play a role in cancer invasion and metastasis? Eur J Cancer Clin Oncol 1987; 23: 583-9.
33. Duffy MJ, McCarthy K. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review). Int J Oncol 1998; 12: 1343-8.
34. Talvensaari-Mattila A, Paakko P, Hoyhtya M, et al. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998; 83: 1153-62.
35. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-73.
36. Zucker S, Pei D, Cao J, Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP). Curr Top Dev Biol 2003; 54: 1-74.
37. Takahashi C, Sheng Z, Horan TP, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. PNAS USA 1998; 95: 13221-6.
38. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178-93.
39. Brown JR, Dubois RN. COX-2: a molecular target for colorectal cancer prevention. J .Clin Oncol 2005; 23: 2840-55.
40. Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 2004; 31: 64-73.
41. Panguluri RC, Long LO, Chen W, et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004; 25: 961-6.
42. Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer 2002; 94: 950-63.
43. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89: 2637-45.
44. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62: 632-5.
45. Singh B, Berry JA, Shoher A, et al. COX-2 involvement in breast cancer metastasis to bone. Oncogene 2007; 26: 3789-96.
46. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000; 406: 747-52.
47. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311-8.